Down syndrome serum marker screening: Decision criteria and implicit values

Health Policy

Volumn 43, Issue 1, 1998, Pages 83-96

  Seror, Valérie ^a   Costet, Nathalie ^a  

^a INSERM   (France)

Author keywords

Decision criteria; Down syndrome; Economic evaluation; Maternal serum markers; Policy options

Indexed keywords

BIOCHEMICAL MARKER;

ABORTION; AMNIOCENTESIS; ARTICLE; COST; COST BENEFIT ANALYSIS; DECISION MAKING; DIAGNOSTIC ACCURACY; DOWN SYNDROME; ECONOMIC EVALUATION; FEMALE; FETUS; FETUS WASTAGE; MATERNAL AGE; MATERNAL SERUM; PREGNANCY; PRENATAL SCREENING; RISK ASSESSMENT;

ADULT; AMNIOCENTESIS; BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; DECISION MAKING; DIAGNOSTIC TESTS, ROUTINE; DOWN SYNDROME; FEMALE; FRANCE; HEALTH CARE RATIONING; HEALTH POLICY; HUMANS; MATERNAL-FETAL EXCHANGE; OUTCOME ASSESSMENT (HEALTH CARE); PREGNANCY; PRENATAL DIAGNOSIS; RISK ASSESSMENT; SOCIAL VALUES;

EID: 0031984345     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(97)00084-5     Document Type: Article

References (42)

1. Hecht C.A., Hook E.B. The imprecision in rates of Down syndrome by 1-year maternal age intervals: a critical analysis of rates used in biochemical screening. Prenatal Diagnosis. 14:1994;729-738.
2. Tabor A., Philip J., Madsen M.et al. Randomized controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet. 1:1986;1287-1293.
3. Kappel B., Nielsen J., Brogaard Hansen K., Mikkelsen M., Therkelsen A.A.J. Spontaneous abortion following mid-trimester amniocentesis. Clinical significance of placental perforation and blood-stained amniotic fluid. British Journal of Obstetrics and Gynaecology. 94:1987;50-54.
4. Eiben B., Osthelder B., Hammans W., Goebel R. Safety on early amniocentesis versus CVS. The Lancet. 344(8932):1994;1303-1304.
5. Giorlandino C., Mobili L., Bilancioni E., D'Alessio P., Carcioppolo O., Gentili P., Vizzone A. Transplantal amniocentesis: is it really a higher-risk procedure? Prenatal Diagnosis. 14:1994;803-806.
6. Johnson J.A., Wilson R.D., Winsor E.J.T., Singer J., Dansereau J., Kalousek D.K. The early amniocentesis study: a randomized clinical trial of early amniocentesis versus midtrimester amniocentesis. Fetal Diagnosis and Therapy. 11:1996;85-93.
7. Dumez Y. Techniques obstétricales pour le diagnostic prénatal [Obstetrical techniques for prenatal diagnosis]. In: Mattei JF, Dumez Y, editors. Le Diagnostic Prénatal. Paris: Doin, 1986.
8. Julian-Reynier C., Aurran Y., Dumaret A.et al. Attitudes towards Down's syndrome: follow up of a cohort of 280 cases. Journal of Medical Genetics. 32:1995;597-599.
9. Hook E.B., Topol B.B., Cross P.K. The natural history of cytogenetically abnormal fetuses detected at midtrimester amniocentesis which are not terminated electively: new data and estimates of the excess and relative risk of late fetal death associated with 47, +21, and some other abnormal karyotypes. American Journal of Human Genetics. 45:1989;855-861.
10. Palomaki G.E., Knight G.J., McCarthy J.et al. Maternal serum screening for fetal Down syndrome in the United States: a 1992 survey. American Journal of Obstetrics and Gynecology. 169(6):1993;1558-1562.
11. American Society of Human Genetics Policy Statement for maternal serum alpha-fetoprotein screening programs and quality control laboratories performing maternal serum and amniotic fluid, American Journal of Human Genetics 1987;40:7-82.
12. Halliday J.L.et al. New estimates of Down syndrome risks at chorionic villus sampling, amniocentesis, and livebirth in women of advanced maternal age from a uniquely defined population. Prenatal Diagnosis. 15:1995;455-465.
13. Verloes A., Schoos R., Herens C., Vintens A., Koulischer L. A prenatal trisomy 21 screening program using a-fetoprotein, human chorionic gonadotropin, and free oestriol assays on maternal dried blood. American Journal of Obstetrics and Gynecology. 172(1,1):1995;167-174.
14. Mancini G., Perona M., Dall'Amico D.et al. Screening for fetal Down's syndrome with maternal serum markers: an experience in Italy. Prenatal Diagnosis. 11:1991;245-252.
15. Seror V. Économie de la prévention: l'exemple du dépistage prénatal [Prevention economics: The example of prenatal diagnosis}, Editions INSERM-Documentation Française. Paris: Collection Questions en Santé Publique, 1995.
16. Hook E.B., Fabia J.J. Frequency of Down Syndrome in livebirth by simple year maternal age interval: Results of a Massachusetts study. Teratology. 17:1978;223-228.
17. Cuckle H. Improved parameters for risk estimation in Down's syndrome screening. Prenatal Diagnosis. 15:1995;1057-1065.
18. Crossley J.A., Aitken D.A., Connor J.M. Prenatal screening for chromosomal abnormalities using maternal serum chorionic gonadotropin, a fetoprotein and age. Prenatal Diagnosis. 11:1991;83-101.
19. Aymé S., Aurran Y., Chabal F.et al. Évaluation du risque de Trisomie 21 par dosage sérique de l'hormone gonadotrophique chorionique et de l'alpha-fetoproteine: Résultats de l'enquête pilote nationale [Evaluation of Down syndrome risk using chorionic gonadotropin and alpha-fetoprotein serum markers: Results of a national pilot study]. Contraception Fertility and Sexuality. 21(2):1993;133-143.
20. Cuckle H., Densem J., Wald N. Repeat maternal serum testing in multiple marker Down's syndrome screening programmes. Prenatal Diagnosis. 14:1994;603-607.
21. Spencer K., Coombes E.J., Mallard A.S.et al. Free beta choriogonadotropin in Down's Syndrome screening: a multicentre study of its role compared with other biochemical markers. Annals of Clinical Biochemistry. 29:1992;506-518.
22. Wald N.J., Cuckle H.S., Densem J.W.et al. Maternal screening for Down's Syndrome in early pregnancy. British Medical Journal. 297:1988;883-887.
23. Wald N.J., Kennard A., Watt H.C.et al. Value of maternal serum unconjugated oestriol measurement in prenatal screening for Down syndrome. Prenatal Diagnosis. 14:1994;699-706.
24. Wald N.J., Watt H.C. Choice of serum markers in antenatal screening for Down's syndrome. Journal of Medical Screening. 1:1994;117-120.
25. Haddow J.E., Palomaki G.E., Knignt G.J.et al. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. New England Journal of Medicine. 330:1994;1114-1118.
26. Wald N.J., Kennard A., Densem J.W.et al. Antenatal maternal serum screening for Down"s Syndrome: results of a demonstration project. British Medical Journal. 305:1992;391-394.
27. Mishan EJ, Cost-Benefit Analysis, London: Allen and Unwin, 1972.
28. Seror V., Muller F., Moatti J.P.et al. Economic assessment of maternal serum screening for Down's syndrome using human chorionic gonadotropin. Prenatal Diagnosis. 13:1993;281-292.
29. Shackley P., McGuire A., Boyd P.A.et al. An economic appraisal of alternative pre-natal screening for Down's syndrome. Journal of Public Health and Medicine. 15(2):1993;175-184.
30. Roelofsen E.E.C., Kamerbeek L.I., Tymstra T.J.et al. Women's opinions on the offer and use of maternal serum screening. Prenatal Diagnosis. 13:1993;741-747.
31. Julian-Reynier C., Macquart-Moulin G., Moatti J.P.et al. Attitudes of women of childbearing age towards prenatal diagnosis in Southeastern France. Prenatal Diagnosis. 13:1993;613-627.
32. Lowry D.L.B., Campbell S.A., Krivchenia E.L.et al. Impact of abnormal second-trimester maternal serum single double and triple screening on patient choices about prenatal diagnosis. Fetal Diagnosis and Therapy. 10:1995;286-289.
33. Briard M.L. La politique de diagnostic anténatal en France. Bilan de onze années [Prenatal diagnosis policy in France: evaluation after 11 years of implementation]. Réadaptation. 384:1991;14-17.
34. Ganiats T.H., Halverson A.L., Bogart M.H. Incremental cost-effectiveness of incorporating oestriol evaluation in Down syndrome screening programmes. Prenatal Diagnosis. 14:1994;527-535.
35. Dupont A., Vaeth M., Videbech P. Mortality and life expectancy of Down's syndrome in Denmark. Journal of Mental Deficiency Research. 30:1986;111-120.
36. Baird P.A., Sadovnick A.D. Life expectancy in Down syndrome. Journal of Pediatrics. 110:1987;849-854.
37. Baird P.A., Sadovnick A.D. Life tables for Down syndrome. Human Genetics. 82:1989;291-292.
38. Gardent H., Fardeau M., Lanoë J.L.et al. Analyse économique de la diffusion d'une innovation médicale: l'exemple du diagnostic prénatal par amniocentèse précoce (2ème partie: l'aide à la décision en santé publique pour la diffusion optimale d'une innovation) [Economic analysis of a medical innovation's propagation: the example of prenatal diagnosis using early amniocentesis (2nd part: Public health decision aid for optimal propagation of an innovation]. Revue Epidemiologie et Santé Publique. 32:1984;97-106.
39. Culyer A.J. The morality of efficiency in health care: some uncomfortable implications. Health Economics. 1:1992;7-18.
40. Johannesson M., Jönsson B., Karlsson G. Outcomes measurement in economic evaluation. Health Economics. 5:1996;279-296.
41. Shackley P., Cairns J. Evaluating the benefits of antenatal screening: an alternative approach. Health Policy. 36:1996;103-115.
42. Press N.A., Browner C.H. 'Collective fiction': similarities in reasons for accepting maternal serum alpha-fetoprotein screening among women of diverse ethnic and social class backgrounds. Fetal Diagnosis and Therapy. 8(1):1993;97-106.